Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Open-Label Dose Escalation Trial Evaluating The Safety And Immunogenicity Of Sequential Administration Of Recombinant DNA And Adenovirus Expressing L523S Protein In Patients With Early Stage Non-Small Cell Lung Cancer

NCT00062907 is registered in ClinicalTrials.gov with Corixa Corporation as lead sponsor.

NCT NCT00062907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00062907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Open-Label Dose Escalation Trial Evaluating The Safety And Immunogenicity Of Sequential Administration Of Recombinant DNA And Adenovirus Expressing L523S Protein In Patients With Early Stage Non-Small Cell Lung Cancer
Lead sponsor
Corixa Corporation
Phase
Phase 1
Overall status
Unknown status
Start date
May 31, 2003
Completion date
Not reported
Enrollment
9
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer